How to cure Covid19 through Medicinal Plants


Chinese Scientists find Extract from TCM Treat COVID

Chinese doctors have obtained a patent for their work using cepharanthine, a chemical derived from traditional Chinese herbal medicine, to combat SARS-CoV-2, which has had promising results.

A patent has been granted to Chinese doctors for their work in combating SARS-CoV-2 with cepharanthine, a substance derived from traditional Chinese herbal therapy, which has shown promising effects.

Tong said he tested the efficiency of the chemical to limit the SAR-CoV-2 with scientists from the Wuhan Institute of Virology's Shi Zhengli and China's top respiratory specialist Zhong Nanshan's teams.

According to information supplied to the Global Times by Tong, the inhibition rate of cepharanthine at low doses can still reach as high as 100%.

Cepharanthine is a substance derived from Chinese herbal medicine. Researchers discovered that it can stop SARS-CoV-2 from infecting target cells by preventing viral binding. According to Tong, it can also inhibit viruses like HIV, SARS, HBV, and Ebola, making it a possible broad-spectrum anti-virus medication.

The treatment has been used on cancer patients for 40 years to boost their white blood cell count. So it's safe, according to Tong.

In early 2020, the researchers discovered the compound's promise in treating COVID-19, according to Tong. His team received the patent on May 10 as a result of widespread flare-ups that raised public expectations for more effective treatments and vaccinations.

Many other Chinese enterprises and researchers are speeding up development in addition to Tong's team's study, as experts underlined that successful therapies are one of the fundamental criteria for China to safely restart internal and international exchanges.

As of Friday, there were 21 domestic COVID-19 medications in development, six of which had entered phase III clinical trials, according to industrial analysis.

One of the most targeted candidates is VV116, an oral anti-SARS-CoV-2 nucleoside candidate developed jointly by the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Wuhan Institute of Virology. According to some experts, mid-term results from the medicine's phase III clinical trials might be announced next week, and the drug could be licensed for emergency use in China by mid-June.


Chinese Traditional Medicines

Chinese Herbals 

Chinese Cultural medicines 

Chinese Historic medicines

Chinese Old method for diagnosis of diseases 

China famous medicines  

Post a Comment